1. Individualizing Care in HIV: A Critical Review of Treatment Options Presented by The Johns Hopkins University School of Medicine Produced in collaboration with ViralEd LLC Supported by an educational grant from Merck & Co., Inc.

2. Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Richard Elion, MD Ian Frank, MD

3. Accreditation Statement: The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To obtain CME credit, after viewing this material go to (Insert Link to Medipix module via VE.com) and click on “CME Post-Test and Evaluation”

4. This program is made possible through an educational grant from Merck & Co.

5. Program Objectives At the conclusion of this activity the participant should be: 1. more knowledgeable regarding the importance of individualizing ARV therapy; 2. able to explain the role individualizing ARV therapy has in improving treatment outcomes; 3. able to explain and use in clinical settings the skills needed to gather knowledge regarding the patient and establish a trusting relationship that furthers the exchange of information between clinician and patient needed to accomplish individualization of care; 4. able to apply in clinical practice the concepts important in individualizing ARV therapy including considering and weighing the characteristics of the ARV therapy options available and applying this knowledge to the characteristics of the individual patient to arrive at the optimal choice of ARV therapy for that individual.

6. Course Directors John Bartlett, MD Professor of Medicine Johns Hopkins School of Medicine Baltimore, Maryland Calvin J. Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts

7. Faculty Richard A. Elion, MD Associate Professor of Clinical Medicine George Washington University Medical Center Washington, DC Ian Frank, MD Associate Professor of Medicine, Director, Antiretroviral Clinical Research University of Pennsylvania Philadelphia, Pennsylvania

8. Full Disclosure Policy Affecting CME Activities As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturers of any commercial products discussed in an educational presentation. The disclosures of the faculty for this program can be found on viraled.com and are presented in the following slides:

9. Disclosures John Bartlett, MD –Honorarium Agreements: Abbott Labs –Consulting Agreements: Johnson & Johnson; Pfizer; Tibotec Cal Cohen, MD –Grant/Research Support: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Tobira –Speakers' Bureau: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Tobira –Consulting Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Tobira; Myriad –Honorarium Agreements: Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Myriad

10. Participant Disclosures Richard Elion, MD –Grant/Research Support: Gilead Sciences; Bristol-Myers Squibb; Tibotec; GlaxoSmithKline; Tobira; Rapid Pharm –Consulting Agreements/Speaker Bureau: Gilead Sciences; Bristol-Myers Squibb; Tibotec –Honorarium: Gilead Sciences; Bristol-Myers Squibb; Tibotec; GlaxoSmithKline Ian Frank, MD –Grant/Research Support: Merck & Co; Bavarian Nordic –Consulting Agreements: Bristol-Myers Squibb; Pfizer; Gilead Sciences; Tibotec; Abbott Laboratories –Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Gilead Sciences; Tibotec This presentation will include information on off-label uses of lopinavir/r, atazanavir, raltegravir, maraviroc, and etravirine.

11. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

12. Individualizing Care Topics 1.When to Start 2.What to Start: ARV Naïve 3.What to Start: ARV Experienced